Engineered immune cells take aim at Hard-to-Treat colorectal cancer
NCT ID NCT07152210
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study tests a new treatment called CAR-T cell therapy for people with advanced colorectal cancer that has not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two proteins (CDH17 and GUCY2C) found on cancer cells. The goal is to see if it is safe and can shrink tumors. About 20 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dongguan Taixin Hospital
RECRUITINGDongguan, Guangdong, 523125, China
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.